Imunon, Inc. (NASDAQ:IMNN) Given Average Recommendation of “Hold” by Brokerages

Shares of Imunon, Inc. (NASDAQ:IMNN) have earned a consensus rating of “Hold” from the five analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $232.50.

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Thursday, January 22nd. Brookline Capital Management restated a “buy” rating on shares of Imunon in a report on Wednesday, January 7th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Imunon stock. Riverview Capital Advisers LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 193.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,364 shares of the company’s stock after purchasing an additional 22,649 shares during the period. Riverview Capital Advisers LLC owned 1.41% of Imunon worth $176,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Stock Down 1.6%

Shares of IMNN stock opened at $3.07 on Friday. The firm has a market capitalization of $9.42 million, a P/E ratio of -0.32 and a beta of 2.14. Imunon has a twelve month low of $2.99 and a twelve month high of $41.22. The stock’s fifty day simple moving average is $3.69 and its 200 day simple moving average is $4.93.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.57. As a group, equities research analysts expect that Imunon will post -1.68 EPS for the current fiscal year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.